Asterias Biotherapeutics Reports First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c
May 16, 2016 4:07 PM EDTAsterias Biotherapeutics (NYSE: AST) reported Q1 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $870 thousand.
For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.
... More